Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 2/20 | 1.00 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.74 |
| ▸ | CASP6 | P55212 | 3/20 | 0.67 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.67 |
| ▸ | NT5E | P21589 | 2/20 | 0.63 |
| ▸ | NSD2 | O96028 | 2/20 | 0.60 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.60 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.60 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.60 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | CD40 | P25942 | 1/20 | 0.48 |
| ▸ | CD40LG | P29965 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | TIMP3 | P35625 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29349608 | 1.00 | PRMT1 (1.00) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL6079067 | 1.00 | PRMT1 (1.00) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL18134576 | 0.92 | PRMT1 (0.84) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL10014033 | 0.92 | PRMT1 (0.84) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL8416221 | 0.91 | PRMT1 (0.83) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL11342001 | 0.91 | PRMT1 (0.82) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL29384348 | 0.89 | PRMT1 (0.81) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL10900036 | 0.89 | PRMT1 (0.81) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL6078935 | 0.88 | PRMT1 (0.78) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL22488772 | 0.88 | PRMT1 (0.78) | PRMT1SIRT1CASP6CTDSP1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4591604-A | Method of inhibiting the complement system by administering multisulfonated naphthalene ureas | AMERICAN CYANAMID COMPANY (US) | 1986-05-27 | — | — | US | claimed |
| US-20230382945-A1 | THERAPEUTIC AGENTS AND METHODS | POP TEST ONCOLOGY LLC (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382945-A1 | THERAPEUTIC AGENTS AND METHODS | POP TEST ONCOLOGY LLC (US) | 2023-11-30 | — | — | US | disclosed |
| US-11702443-B2 | Therapeutic agents and methods | POP TEST ONCOLOGY LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702443-B2 | Therapeutic agents and methods | POP TEST ONCOLOGY LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220168329-A1 | COMBINATORIAL DRUG TREATMENT OF CANCER | UNIVERSITY OF VIRGINIA | 2022-06-02 | — | — | US | disclosed |
| US-11224599-B2 | Therapeutic agents and methods | POP TEST ONCOLOGY LLC | 2022-01-18 | — | — | US | disclosed |
| US-20210353623-A1 | THERAPEUTIC AGENTS AND METHODS | POP TEST ONCOLOGY LLC | 2021-11-18 | — | — | US | disclosed |
| US-11040037-B2 | Therapeutic agents and methods | POP TEST ONCOLOGY LLC | 2021-06-22 | — | — | US | disclosed |
| US-20190054070-A1 | Methods and Compositions for Regenerative Synaptogenesis | NEUROTROPE BIOSCIENCE, INC. | 2019-02-21 | — | — | US | disclosed |
| US-6458998-B1 | NAPHTHALENEUREAS AS ANTIDIABETIC AGENTS | TELIK, INC. | 2002-10-01 | — | — | US | disclosed |
| US-6120561-A | Process for the preparation of low-salt, liquid dyestuff preparations | BAYER AKTIENGESELLSCHAFT (DE) | 2000-09-19 | — | — | US | disclosed |
| US-5697985-A | PREPARING AQUEOUS SLURRY OF ALKALI METAL SALT OF AZO DIRECT DYE, ADDING VISCOSITY ENHANCING AGENT | BAYER CORPORATION (US) | 1997-12-16 | — | — | US | disclosed |
| EP-0747450-A2 | Process for the preparation of storage-stable dye dispersions | Bayer Corporation (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0235524-B1 | PROCESS FOR THE PREPARATION OF CONCENTRATED SOLUTIONS OF ANIONIC DYES | BAYER AG (DE) | 1992-04-15 | — | — | EP | disclosed |
| US-4933436-A | Process for the preparation of stable aqueous solutions of anionic dyestuffs by conducting diazotization in the presence of an aromatic sulphonic acid | BAYER AKTIENGESELLSCHAFT (DE) | 1990-06-12 | — | — | US | disclosed |
| US-4599203-A | Multisulfonated naphthalene ureas useful as complement inhibitors | AMERICAN CYANAMID COMPANY (US) | 1986-07-08 | — | — | US | disclosed |
| US-4591604-A | Method of inhibiting the complement system by administering multisulfonated naphthalene ureas | AMERICAN CYANAMID COMPANY (US) | 1986-05-27 | — | — | US | disclosed |
| US-4163012-A | DIAZOTIZATION IN THE PRESENCE OF CALCIUM HYDROXIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1979-07-31 | — | — | US | disclosed |
| US-4118182-A | Solutions of azo dyes derived from 4-4-diamino-2,2-stilbenedisulfonic acid | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168329-A1 | COMBINATORIAL DRUG TREATMENT OF CANCER | DDIT3, PRMT3, PRMT1 | PRMT1 3/4885SIRT1 1279/4885CASP6 1575/4885 |
| US-11702443-B2 | Therapeutic agents and methods | NR1H4, NR3C1, NR3C2 | PRMT1 3314/4885SIRT1 2521/4885CASP6 2608/4885 |
| US-20230382945-A1 | THERAPEUTIC AGENTS AND METHODS | NR1H4, NR3C1, NR3C2 | PRMT1 3314/4885SIRT1 2521/4885CASP6 2608/4885 |
| US-11224599-B2 | Therapeutic agents and methods | NR1H4, NR3C1, NR3C2 | PRMT1 3314/4885SIRT1 2521/4885CASP6 2608/4885 |
| US-20210353623-A1 | THERAPEUTIC AGENTS AND METHODS | NR1H4, NR3C1, NR3C2 | PRMT1 3314/4885SIRT1 2521/4885CASP6 2608/4885 |
| US-20190054070-A1 | Methods and Compositions for Regenerative Synaptogenesis | PRMT7, DCX, EZH2 | PRMT1 4/4885SIRT1 481/4885CASP6 3580/4885 |
| US-11040037-B2 | Therapeutic agents and methods | NR1H4, NR3C1, NR3C2 | PRMT1 3314/4885SIRT1 2521/4885CASP6 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.